Analysis of the duration of combination therapy that is necessary for hepatitis C (HCV) genotype 1 eradication
| ISRCTN | ISRCTN56141572 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN56141572 |
| Secondary identifying numbers | N0263132921 |
- Submission date
- 30/09/2004
- Registration date
- 30/09/2004
- Last edited
- 18/07/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr N V Naoumov
Scientific
Scientific
General Medicine (Hepatology)
Institute of Hepatology
University College London
69-75 Chenies Mews
London
WC1E 6HX
United Kingdom
| Phone | +44 (0)20 7388 2013 |
|---|---|
| n.naoumov@ucl.ac.uk |
Study information
| Study design | Randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
| Scientific title | Analysis of the duration of combination therapy that is necessary for hepatitis C (HCV) genotype 1 eradication |
| Study objectives | What is the duration of combination therapy required in order to produce a sustained viral clearance in hepatitis C infected patients |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Infections and Infestations: Hepatitis C |
| Intervention | Randomised Controlled Trial 1. Chemotherapy 1 2. Chemotherapy 2 |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | |
| Primary outcome measure | Viral clearance |
| Secondary outcome measures | Not provided at time of registration |
| Overall study start date | 01/10/2003 |
| Completion date | 01/10/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Both |
| Target number of participants | 50 |
| Key inclusion criteria | 50 patients from Hepatology |
| Key exclusion criteria | Does not match inclusion criteria |
| Date of first enrolment | 01/10/2003 |
| Date of final enrolment | 01/10/2005 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
University College London
London
WC1E 6HX
United Kingdom
WC1E 6HX
United Kingdom
Sponsor information
Department of Health
Government
Government
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
| Website | http://www.dh.gov.uk/Home/fs/en |
|---|
Funders
Funder type
Hospital/treatment centre
University College London Hospitals NHS Trust (UK)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Editorial Notes
18/07/2016: No publications found, verifying study status with principal investigator.
